SIREN : 817882178
MEDICINA is a French company founded 10 years ago, specialized in the sector Supports juridiques de gestion de patrimoine immobilier. Based in TASSIN-LA-DEMI-LUNE (69160), this company of category PME shows in 2024 a revenue of 2.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 2 217 221 € | 1 969 785 € | 1 333 534 € | 1 620 000 € | 2 258 000 € | 1 087 000 € | 60 000 € |
| Net income | -493 914 € | -14 771 € | -723 137 € | -1 054 733 € | -23 282 € | 12 822 € | 1 136 € |
| EBITDA | 204 019 € | 51 551 € | -406 030 € | -593 499 € | 28 507 € | -11 341 € | 1 335 € |
| Net margin | -22.3% | -0.7% | -54.2% | -65.1% | -1.0% | 1.2% | 1.9% |
In 2024, MEDICINA achieves revenue of 2.2 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +57.0%. Vs 2023, growth of +13% (2.0 M€ -> 2.2 M€). After deducting consumption (0 €), gross margin stands at 2.2 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 204 k€, representing 9.2% of revenue. Positive scissor effect: EBITDA margin improves by +6.6 pts, sign of improved operational efficiency. This level of operating margin is satisfactory for the sector. Net income is negative at -494 k€ (-22.3% of revenue), which will impact equity.
2 217 221 €
2 217 221 €
204 019 €
144 217 €
-493 914 €
9.2%
The debt ratio (= Financial debt / Equity x 100) stands at 4738%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 1%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 2.9 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 14.2% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
4737.567%
0.849%
14.248%
2.881
0.4%
In 2024, the debt ratio of MEDICINA (4737.57) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of MEDICINA (0.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of MEDICINA (2.88) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 266.37. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 34.9x. Operating income very largely covers interest expenses: high safety margin.
266.372
34.922
In 2024, the liquidity ratio of MEDICINA (266.37) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of MEDICINA (34.9x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 70 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 98 days. Favorable situation: supplier credit is longer than customer credit by 28 days. Overall, WCR represents 193 days of revenue, i.e. 1.2 M€ to permanently finance. Over 2016-2024, WCR increased by +1228%, requiring additional financing.
1 186 413 €
70 j
98 j
0 j
193 j
Based on 277 transactions of similar company sales (all years), the value of MEDICINA is estimated at 406 375 € (range 173 202€ - 1 027 851€). With an EBITDA of 204 019€, the sector multiple of 1.3x is applied. The price/revenue ratio is 0.29x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare MEDICINA with other companies in the same sector:
Voir toutes les statistiques du secteur Supports juridiques de gestion de patrimoine immobilier
The revenue of MEDICINA in 2024 is 2.2 M€.
MEDICINA recorded a net loss in 2024.
The headquarters of MEDICINA is located in TASSIN-LA-DEMI-LUNE (69160), in the department Rhone.
The tax return of MEDICINA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
MEDICINA operates in the sector Supports juridiques de gestion de patrimoine immobilier (NAF code 68.32B). See the 'Sector positioning' section above to compare the company with its competitors.